Published 2022
| Version v1
Journal article
Open
Dynamic changes in metabolites of the kynurenine pathway in Alzheimers disease, Parkinsons disease, and Huntingtons disease: A systematic Review and meta-analysis
Authors/Creators
- 1. Student Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences
- 2. Student Research Committee, Faculty of Medicine, Medical University of Qom
- 3. Department of Neurology, Faculty of Medicine Medical Sciences, Islamic Azad University
- 4. Faculty of Medicine, Shahid Beheshti University of Medical Sciences
- 5. Department of Biology, Faculty of Science, University of British Columbia, Okanagan Campus, Kelowna, BC, Canada
- 6. Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences
Description
Background: Tryptophan (TRP) is an essential amino acid that must be provided in the diet. The kynurenine pathway (KP) is the main route of TRP catabolism into nicotinamide adenosine dinucleotide (NAD+), and metabolites of this pathway may have protective or degenerative effects on the nervous system. Thus, the KP may be involved in neurodegenerative diseases. Objectives: The purpose of this systematic review and meta-analysis is to assess the changes in KP metabolites such as TRP, kynurenine (KYN), kynurenic acid (KYNA), Anthranilic acid (AA), 3-hydroxykynurenine (3-HK), 5-Hydroxyindoleacetic acid (5-HIAA), and 3-Hydroxyanthranilic acid (3-HANA) in Alzheimers disease (AD), Parkinsons disease (PD), and Huntingtons disease (HD) patients compared to the control group. Methods: We conducted a literature search using PubMed/Medline, Scopus, Google Scholar, Web of Science, and EMBASE electronic databases to find articles published up to 2022. Studies measuring TRP, KYN, KYNA, AA, 3-HK, 5-HIAA, 3-HANA in AD, PD, or HD patients and controls were identified. Standardized mean differences (SMDs) were used to determine the differences in the levels of the KP metabolites between the two groups. Results: A total of 30 studies compromising 689 patients and 774 controls were included in our meta-analysis. Our results showed that the blood levels of TRP was significantly lower in the AD (SMD=-0.68, 95% CI=-0.97 to -0.40, p=0.000, I2 = 41.8%, k=8, n=382), PD (SMD=-0.77, 95% CI=-1.24 to -0.30, p=0.001, I2 = 74.9%, k=4, n=352), and HD (SMD=-0.90, 95% CI=-1.71 to-0.10, p=0.028, I2 = 91.0%, k=5, n=369) patients compared to the controls. Moreover, the CSF levels of 3-HK in AD patients (p=0.020) and the blood levels of KYN in HD patients (p=0.020) were lower compared with controls. Conclusion: Overall, the findings of this meta-analysis support the hypothesis that the alterations in the KP may be involved in the pathogenesis of AD, PD, and HD. However, additional research is needed to show whether other KP metabolites also vary in AD, PD, and HD patients. So, the metabolites of KP can be used for better diagnosing these diseases. Copyright 2022 Fathi, Vakili, Yaghoobpoor, Tavasol, Jazi, Hajibeygi, Shool, Sodeifian, Klegeris, McElhinney, Tavirani and Sayehmiri.